North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
- 2026 年市場規模
- USD 1,615.5 Mn
- 2033 年預估規模
- USD 2,111.7 Mn
- 年複合成長率 CAGR
- 5.5%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, Others), Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), By Infection Type (Hospital Acquired ABSSSI , Community Acquired ABSSSI), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe)
報告摘要
Acute bacterial skin and skin structure infections (ABSSSI) are the skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. The increasing pediatric patient pool is targeted by the manufacturers to enhance its product portfolio with pediatric specific products. For instance, in 2016, Allergan plc received US FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for ABSSSI indication in pediatric.
Market Dynamics
The major market driver for growth of North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received U.S. FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received U.S. FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.
However, misuse of drugs causes antibiotic resistance which is a major factor hindering growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market. For example, according to the Centers for Disease Control and Prevention data has shown that treatment indication, choice of agent, or duration of antibiotic therapy is incorrect in 30-50% of cases. Moreover, 30-60% of antibiotics prescribed in intensive care units (ICUs) have been found to be unnecessary, inappropriate, or suboptimal.
Key features of the study
• This report provides in-depth analysis of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026-2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study are Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market, research and consulting firms, new entrants, and financial analysts.
North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Segmentation
• By Drug Type
o Oral & Parenteral Antibiotics
Vancomycin
Linezolid
Clindamycin
Ceftaroline
Daptomycin
Dalbavancin
Tedizolid
Others
o Topical Antibiotics
Hydrogen Peroxide
Fusidic Acid
Mupirocin
Retapamulin
Povidone-Iodine
• By Infection Type
o Hospital Acquired ABSSSI
o Community Acquired ABSSSI
• By Route of Administration
o Oral
o Parenteral
o Topical
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region
o North America
U.S.
Canada
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
• Key Players
o Merck & Co., Inc.
o Pfizer Inc.
o GlaxoSmithKline plc
o Teva Pharmaceutical Industries Ltd.
o Paratek Pharmaceuticals, Inc.
o Melinta Therapeutics, Inc.
o Arrevus, Inc.
o AbbVie Inc.
o Aurobindo Pharma Ltd.
o Amneal Pharmaceuticals LLC
o Sun Pharmaceutical Industries Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Infection Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Oral & Parenteral Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Vancomycin
o Linezolid
o Clindamycin
o Ceftaroline
o Daptomycin
o Dalbavancin
o Tedizolid
o Others
o Topical Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Hydrogen Peroxide
o Fusidic Acid
o Mupirocin
o Retapamulin
o Povidone-Iodine
5. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Acquired ABSSSI
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Community Acquired ABSSSI
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
6. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Topical
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
7. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
8. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
9. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Merck & Co Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
GlaxoSmithKline plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Paratek Pharmaceuticals, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Melinta Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Arrevus, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AbbVie Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Aurobindo Pharma Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Amneal Pharmaceuticals LLC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Sun Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們